Table 4.
Univariate analysis of liver progression-free survival.
| Variables | Number (%) | Kaplan–Meier Median LPFS (Months, 95%CI) |
p-Value (Log-Rank) |
Cox Proportional Hazards Hazard Ration (95%CI) |
p-Value (Cox) |
|---|---|---|---|---|---|
| Primary Metastases | |||||
| Yes No |
16 (45.7%) 19 (54.3%) |
7 (3.4–10.6) 19 (4.1–33.9) |
0.036 | 2.5 (1.1–6.2) | 0.048 |
| Extrahepatic Metastases | |||||
| Yes No |
22 (62.8%) 13 (37.2%) |
8 (3.5–12.5) 9 (5.8–12.2) |
0.748 | 1.1 (0.5–2.7) | 0.754 |
| Liver Involvement | |||||
| Bilobar Single lobe |
29 (82.8%) 6 (17.1%) |
9 (6.4–11.6) 4 (1.9–6.1) |
0.815 | 0.9 (0.3–2.7) | 0.818 |
| Baseline Liver Volume | |||||
|
1.5 L 1.5 L |
25 (71.4%) 10 (28.6%) |
10 (7.6–12.4) 7 (0.8–13.2) |
0.838 | 1.1 (0.4–2.9) | 0.842 |
| Child-Turcotte-Pugh Class | |||||
| B A |
8 (22.9%) 27 (77.1%) |
39 (N/A) 9 (6.3–11.7) |
0.892 | 1.1 (0.3–3.3) | 0.894 |
| Baseline MELD | |||||
|
9 9 |
8 (22.9%) 27 (77.1%) |
9 (0.0–18.8) 8 (4.9–11.1) |
0.984 | 1.0 (0.4–2.8) | 0.984 |
| Baseline ALBI grade | |||||
| Grade 2–3 Grade 1 |
22 (62.9%) 13 (37.1%) |
8 (4.4–11.6) 10 (6.1–13.9) |
0.508 | 0.8 (0.3–1.8) | 0.521 |
| Interim Chemotherapy | |||||
| Yes No |
14 (40%) 21 (60%) |
8 (6.5–9.5) 10 (0.0–22.5) |
0.463 | 1.4 (0.6–3.3) | 0.477 |
| Chemotherapy Pre-TARE | |||||
| Yes No |
27 (77.1%) 8 (22.9%) |
9 (6.1–11.9) 8 (0.0–37.8) |
0.416 | 1.5 (0.5–4.2) | 0.429 |
| Liver Surgery Pre-TARE | |||||
| Yes No |
9 (25.7%) 26 (74.3%) |
10 (0.0–24.6) 9 (6.2–11.8) |
0.595 | 1.3 (0.5–3.1) | 0.606 |
| Radiotherapy Pre-TARE | |||||
| Yes No |
16 (45.7%) 19 (54.3%) |
8 (4.9–11.0) 10 (4.7–15.4) |
0.713 | 0.8 (0.4–1.9) | 0.720 |
| Liver-directed therapy Pre-TARE | |||||
| Yes No |
3 (8.6%) 32 (91.4%) |
8 (1.6–14.4) 10 (5.7–14.3) |
0.248 | 2.0 (0.6–7.1) | 0.272 |
| Type of Y90 Microspheres | |||||
| Resin (SIR) Glass (Theraspheres) |
31 (88.6%) 4 (11.4%) |
9 (6.4–11.6) 7 (2.2–11.8) |
0.911 | 1.1 (0.3–3.8) | 0.913 |
| TARE Distribution | |||||
| Bilobar Single Lobe/Segmental |
22 (62.8%) 13 (37.2%) |
10 (7.4–12.6) 8 (2.9–13.1) |
0.848 | 0.9 (0.3–2.2) | 0.852 |
| Baseline ECOG | |||||
| 2 0–1 |
6 (17.2%) 29 (82.8%) |
8 (N/A) 10 (7.1–10.8) |
0.148 | 2.5 (0.7–9.1) | 0.173 |
| Histotype | |||||
| Leiomyosarcoma Other |
20 (57.1%) 15 (42.9%) |
8 (6.4–9.6) 10 (0.0–22.6) |
0.320 | 0.6 (0.3–1.6) | 0.337 |
ECOG, Eastern Cooperative Oncology Groups; ALBI, albumin–bilirubin; MELD, Model for End-Stage Liver Disease; N/A, not applicable; Interim Chemotherapy, chemotherapy administered between TARE and the first detected liver disease progression; TARE, trans-arterial radioembolization; Y90, Yttrium-90; 95%CI, 95% confidence interval.